Zygmont Chester Stanley III 4

What Happened
Chester S. Zygmont III, Chief Financial Officer of Revelation Biosciences (REVB), had 13,285 shares sold on April 30, 2026 to satisfy required tax withholding related to vested restricted stock. The sale generated approximately $14,614 in proceeds based on a weighted average price of $1.10 per share (individual sale prices ranged $1.09–$1.13).

Key Details

• Transaction date: 2026-04-30; Form 4 filed 2026-05-01 (appears timely).
• Transaction type: Code F — shares sold by the issuer to satisfy tax withholding upon vesting (mandatory).
• Shares sold: 13,285; weighted avg price reported $1.10; reported range $1.09–$1.13.
• Proceeds: ~$14,614.
• Shares owned after transaction: Not specified in this filing.
• Relevant footnotes: F1 (mandatory tax-withholding sale), F2 (price is weighted avg; multiple sale prices disclosed), F3 and F4 note some shares are held in entities (The Zygmont Family Trust and Czeslaw Capital Fund, LLC) for which Zygmont is trustee/sole manager.

Context
This was a mandatory, routine tax-withholding sale tied to restricted stock vesting (not an opportunistic open-market sale). Such F-code transactions typically reflect administrative requirements rather than a signal about the insider’s view of company prospects.